Of direct relevance and validating these results, similar findings have been shown in human AD tissue from TREM2 variant carriers, in which microglial responses to pathology are suppressed in newly formed pathological areas but exacerbated in more advanced pathological brain areas [70]. This evidence concerns the gene TREM2 and Alzheimer disease.